<DOC>
	<DOCNO>NCT00516672</DOCNO>
	<brief_summary>This two part phase I study Japanese patient determine safety , tolerability pharmacokinetics pazopanib monotherapy pazopanib combination lapatinib .</brief_summary>
	<brief_title>Phase I Study Pazopanib Alone In Combination With Lapatinib Japanese Patients With Solid Tumors .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criterion : Signed informed consent . Histologically cytologically confirm diagnosis advance solid tumor . Women men potential child must willing practice acceptable method birth control study . ECOG performance status 0 1 . Adequate bone marrow reserve hepatorenal function . Able swallow retain oral medication . For combo part , leave ventricular ejection fraction within normal range 50 % . Exclusion criterion : Prior treatment pazopanib , lapatinib combo part . Clinically significant gastrointestinal abnormality . Sevier diseases condition cancer . Poorly control hypertension . Use warfarin therapeutic anticoagulation . Use antiangiogenesis agent , ErbB inhibitor combo part . Unresolved and/or unstable toxicity Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>lapatinib ,</keyword>
	<keyword>cancer</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>safety ,</keyword>
	<keyword>pazopanib ,</keyword>
	<keyword>Japanese patient ,</keyword>
</DOC>